GnRH agonist therapy and premature ovarian failure

In young women who develop breast cancer, ovarian suppression while using triptorelin, a gonadotropin-releasing hormone analog, during the process of chemotherapy proved to reduce the incidence of premature menopause. These findings have been published in the Journal of the American Medical Association in July 2011 and is the result of a study in Italy.

The team of researchers from the Instituto Nazionale per la Ricerca sul Cancro, Genoa, headed by dr. Lucia Del Mastro, underlined that about 6% of women diagnosed with breast cancer under the age of 40 years, and mostly treated with chemotherapy or hormonal therapy. So far, there has been no standard therapies are applied to prevent the occurrence of premature ovarian failure. To investigate the protective effects of temporary ovarian suppression during the treatment of breast cancer, the researchers recruited 281